Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453203 | 0.85 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL218667 | 0.83 | PNP (0.63) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL4446270 | 0.78 | PNP (0.66) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8843873 | 0.73 | PNP (0.54) | PNP | |
| SCHEMBL2940013 | 0.73 | PNP (0.63) | PNPKDM4EMEN1ALDH1A1MAPT | |
| 8-Aminoguanine SCHEMBL21761 | 0.73 | PNP (1.00) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6265336 | 0.73 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3072982 | 0.72 | PNP (0.53) | PNPFGFR1FGFR2 | |
| SCHEMBL10755112 | 0.70 | PNP (0.50) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL5694187 | 0.70 | FGFR1 (0.57) | PNPFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112608313-B | Treatment method of mother liquor precipitate in production of triacetyl ganciclovir | 河北合佳医药科技集团股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-112608313-A | Treatment method of mother liquor precipitate in production of triacetyl ganciclovir | 河北合佳医药科技集团股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-7078524-B2 | Process for the synthesis of ganciclovir | RANBAXY LABORATORIES LIMITED (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040102628-A1 | Process for the synthesis of ganciclovir | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-27 | — | — | US | disclosed |
| EP-0806425-B1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LAB LTD (IN) | 2001-08-29 | — | — | EP | disclosed |
| US-6043364-A | HEATING THE ISOMER IN AN ALKYLATING AGENT IN ABSENCE OF ACID CATALYST AND SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 2000-03-28 | — | — | US | disclosed |
| EP-0976751-A1 | A process for the isomerisation of an N-7 isomer into an N-9 isomer useful in the synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 2000-02-02 | — | — | EP | disclosed |
| US-5821367-A | REACTING A DIACYLGUANINE AND AN ALKYLATING AGENT IN THE ABSENCE OF AN ACID CATALYST AND A SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 1998-10-13 | — | — | US | disclosed |
| EP-0806425-A1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102628-A1 | Process for the synthesis of ganciclovir | TYMP, MTAP, TPMT | PNP 10/4885KDM4E 575/4885MEN1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.